Certara Research Reveals IRA’s Impact on Biosimilar Uptake
RADNOR, PA - August 15, 2024 -- Certara, Inc., a global leader in model-informed drug…
CertaraAugust 15, 2024
Medicines that matter: Biohaven’s Nurtec™ drug development journey
In February 2020, Biohaven Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved…
CertaraAugust 15, 2024
Mastering Value Storytelling in Healthcare: Leveraging Digital Tools to Meet Stakeholders’ Expectations
Everyone loves a good story. Stories are more likely to move and engage people than…
CertaraAugust 14, 2024
Evaluating the IRA’s Impact on Medicare Part B Biosimilar Reimbursement
White paper exploring the IRA’s small but measurable impact in several key areas
CertaraAugust 13, 2024
All you need to know about NCI, CDISC and SDTM controlled terminology
The use of controlled terminology (CT) is vital to successful clinical study build. In clinical…
CertaraAugust 13, 2024
Model-Informed Confidence in Oncology Dose Selection
Discover an oncology-focused company that gained confidence in their dose selection for an AML trial…
CertaraAugust 9, 2024
Go beyond basic validation: Achieve submission-ready datasets with Pinnacle 21 Enterprise
Explore how Pinnacle 21 Enterprise simplifies dataset validation, enhances compliance, and prepares you for regulatory…
CertaraAugust 9, 2024
Digital Payer Portals for Enhanced Value Communication
The trend of using digital tools for communication and information sharing in the life science…
CertaraAugust 9, 2024
Summarize This! GPT Prompts for Regulatory Writers
With the advent of GPTs, regulatory writers face an opportunity and a challenge. The opportunity?…
CertaraAugust 8, 2024
